Infectious Disease General
RSSArticles
-
Pharmacology Watch: HRT - Position Paper Places Benefits in Question
-
Updates: Antiretroviral Therapy and Pregnancy; Cryptococcosis on Vancouver Island; Foodborne Outbreaks
-
Parvovirus B19 Transmissions During Thoracic Surgery from a Pooled Plasma Product
-
Updates: Mosquitoes and Patients with HIV; Pneumococcal Vaccination in SLE and RA; Highly Resistant GC Marches Toward U.S.
-
Smallpox vaccination of some health care workers may not go far enough
-
Smallpox Vaccination Q&A
-
Panel: Early treatment of HCV not clear-cut
-
Surgeon-to-patient HCV infections raise questions
-
Clinical Briefs: Creatine Supplements & Anaerobic Performance; Delayed Prescriptions & Antibiotic Use; Immediate Repair vs. Surveillance of Small AAAs
-
CD4 Lymphocyte Percentage and HIV Disease Progression
This study out of Vanderbilt examined a cohort of 788 eligible patients from their clinic who received their first highly active antiretroviral therapy (HAART) regimen for at least 30 days between January 1998 and January 2003 and had a baseline CD4 lymphocyte determination in the 180 days prior to initiating antiretrovirals or within 45 of starting treatment.